overall survival data in mcrpc
Published 4 years ago • 364 plays • Length 2:49Download video MP4
Download video MP3
Similar videos
-
9:51
overall survival data presented at asco 2020 for nmcrpc
-
7:52
case 3: treatment after progression to mcrpc
-
1:22
cabazitaxel improves rpfs in patients with mcrpc
-
4:56
improving the prognosis for patients with mcrpc
-
16:35
overall survival with sipuleucel-t in patients treated for advanced prostate cancer
-
1:31
investigating prognostic markers for os with lupsma treatment in mcrpc
-
1:19
the need for better surrogate parameters for overall survival in colorectal cancer
-
10:57
cell-free dna genomic and epigenomic analysis to predict survival in mcrpc patients
-
1:32:31
unlocking the power of modern therapeutic regimens for prostate cancer
-
15:06
prostate cancer recurrence - knock it out with proton radiation
-
4:31
diagnosis of stage 3 prostate cancer
-
16:53
perspectives in mcrpc in 2024
-
10:28
anzup therap study (lu-177 psma-617 vs. cabazitaxel): overall survival after 3 years follow-up
-
1:46
os after progression on first novel hormonal therapy in mcspc vs mcrpc
-
2:21
challenging overall survival as an endpoint in ovarian cancer
-
2:16
testing the validity of a prognostic model for castration-resistant prostate cancer
-
1:51
dr. tagawa on remaining questions with psma-targeted radionuclide therapy in mcrpc
-
0:46
ctc hoxb13 rna in mcrpc: abiraterone/enzalutamide impact
-
53:17
targeting advanced prostate cancer with parp inhibitors: who, when and how?
-
5:16
significance of the era 223 trial in mcrpc
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
1:18
results of the latitude trial in high-risk metastatic hormone-naive prostate cancer